Bilaga 4 Tabeller över inkluderade studier/Table over included studies

SBU Utvärderar: Diagnostik och behandling av provocerad vulvodyni/Diagnostics and treatment of provoked vestibulodynia

Rapport nr: 326

SBU Statens beredning för medicinsk och social utvärdering • www.sbu.se
Telefon 08-412 32 00 • Fax 08-411 32 60 • Organisationsnummer 202100-4417
Besöksadress S:t Eriksgatan 117, Stockholm • Postadress Box 6183, 102 33 Stockholm

Table 1 Pharmacological treatment.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
Brown et al. 2018 [1] USA Bachmann et al. 2019 [2] USA	Study design: RCT, multicentre with crossover design Patient characteristics: Provoked localized vulvodynia. n=89. Mean age: 37 (SD 12).	Intervention: Oral gabapentin, 1200 – 3000 mg/day for 6-8 weeks (4 weeks titration +2 weeks maintenance +2 weeks dose-taper in each crossover phase) n=45. Control: Placebo tablets n=44. Follow-up time: 6 weeks post-allocation and 6 weeks after cross-over (data pooled). Drop-out: I: 12/45 (20%) C: 14/44 (32%).	Pain during intercourse: VAS (range 0-10), total crossover data, MD (95% CI): 0.0 (-0.9 to 0.8), n=27 (ns). Pain during tampon test: VAS (range 0-10), total crossover data, MD (95% CI): -0.3 (-0.7 to 0.1), n=83 (ns).	FSFI, total crossover data, adjusted MD (95% CI): 1.3 (0.4 to 2.2) n=63, p=0.008.	Serious adverse events: I: 0/45 (0%) C: 0/44 (0%) Mild adverse events, %: *Rhinitis:* I: 11.2 C: 4.5 *Dizziness:* I: 10.1 C: 3.4 *Nausea:* I: 8.9 C: 3.4 *Headache:* I: 7.9 C: 5.6 *Somnolence:* I: 7.9 C: 4.5 *Bacterial vaginosis:* I: 7.9 C: 4.5 *Fatigue:* I. 5.6 C: 1.1 (all ns).	Risk of bias Low Blinding: Patients and treatment providers blinded.

Author Year Reference Country	**Study design Patient characteristics**	**Intervention Control Follow-up time Drop-outs**	**Results:** **• Pain during intercourse** **• Pain at pressure**	**Results:** **• Sexual function/satisfaction** **• Quality of life** **• Anxiety** **• Depression**	**Results:** **• Adverse events**	**Risk of bias Blinding Comments**
Bornstein et al. 2010 [3] Israel	Study design: NRSI with prospective allocation, single-centre, 3-arm. Patient characteristics: Provoked localized vulvodynia. n=50. Mean age: 24.7 (SD 2.9)	Intervention: Nifedipine cream, 2% or 4%, topical self-administration 4 times daily for 6 weeks I-A (2%) n=10* I-B (4%) n=10*. Control: Placebo cream n=10*. Follow-up time: Immediately post-treatment and 3 months post-treatment. Drop-out: Total: 20/50 (not reported in relation to groups).	Pain during intercourse, VAS (range 0-100), mean (SD): *Post-treatment:* I-A: 61.9 (34.2) I-B: 72.5 (27.6) C: 48.1 (42.8) (ns). *3 months post-treatment:* I-A: 51.5 (36.1) I-B: 69.7 (36.6) C: 57.6 (40.4) (ns). Vulvar pain assessed with q-tip test (range 0-100), mean (SD): *Post-treatment:* I-A: 56.2 (35.5) I-B: 63.5 (34.2) C: 53.4 (35.4) (ns). *3 months post-treatment:* I-A: 47.0 (37.7) I-B: 73.5 (29.4) C: 52.7 (46.6) (ns).		Serious adverse events: I-A: 0/10 (0%) I-B: 0/10 (0%) C: 0/10 (0%). Mild adverse events: “mild irritation felt by some of the participants in the intervention groups”.	Risk of bias: Moderate Blinding: Patients, treatment providers and assessors blinded. Comments: *Number of participants after drop-outs.
Diomande et al. 2019	Study design: RCT, single centre, with a blinded phase	Intervention: I: Botulinum toxin A, 50 units (I-A) or 100 units (I-B)	Marinoff dyspareunia scale (range 0–3), median (IQR) I-A: 1.5 (0–2)		Serious adverse events: I-A: 0/12 (0%)	Risk of bias Low

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
[4] Switzerland	of 3 months and an unblinded exploratory phase (data not extracted). Patient characteristics: Provoked vestibulodynia, according to Friedrich criteria. n=33. Median age: 27 (IQR 24 to 30).	injected subcutaneously into the dorsal vulvar vestibulum at one occasion. n=12 (I-A) and 9 (I-B). Control: Placebo injection (saline) n=12. Follow-up time: 3 months post-allocation. Drop-out: I-A: 0/12 (0%) I-B: 1/9 (11%) C: 1/12 (8%).	I-B: 1.5 (0–3) C: 2 (1-2) (p=0.927). Vulvar pain assessed with cotton swab test, VAS (0-10), mean (SD): I-A: 6.2 (2.60) I-B: 6 (1.77) C: 6.5 (1.31). (p=0.857).		I-B:0/8 (0%) C: 0/11 (0%).	Blinding: Patients, treatment providers and assessors blinded.
Donders et al. 2012 [5] Belgium	Study design: RCT, single centre with crossover design (12+12 weeks separated by a 1-week washout period). Patient characteristics: Provoked localized vulvodynia. n=30.	Intervention: Cutaneous fibroblast lysate cream, topical self-administration of 0.2 mL twice daily for 12 weeks n=15. Control: Placebo cream n=15. Follow-up time: 4-, 12-, 17- and 25-weeks	Pain during sexual activity: VAS (range 0-10), patients with >1 point reduction: *4 weeks post-treatment (before cross-over):* I: 42% C: 15%. *12 weeks post-treatment (before cross-over):* I: 31% C: 0%. Total cross-over data*, VAS change from baseline,		Serious adverse events: I: 0/15 (0%) C: 0/15 (0%). Mild adverse events: I: 3/15 (33%) C: 1/15 (7%) (ns).	Risk of bias: Low Blinding: Patients, treatment providers and assessors blinded. Comment: *There was evidence for a second-order carryover

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
	Mean age: 27 (range 20 to 54)	post-allocation. Drop-out: I: 2/15 (13%) C: 2/15 (13%).	MD (95% CI): *4 weeks post-treatment:* 1.1 (-0.6 to 2.8), n=26, p=0.20. *12 weeks post-treatment:* 1.3 (0.1 to 2.5), n=26 p=0.037. Vulvar pain assessed with q-tip test, VAS (range 1-10), patients with >1 point reduction: *4 weeks post-treatment (before cross-over)*: I: 64% C: 69%. *12 weeks post-treatment (before cross-over):* I: 55%) C: 50%. Total cross-over data*, VAS change from baseline: *4 weeks post-treatment:* p=0.91. *12 weeks post-treatment:*			effect (p = 0.024).

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
			p=0.96.			
Farajun et al. 2012 [6] Israel	Study design: RCT, single centre. Patient characteristics: Provoked vestibulodynia. n=40. Mean age: Not reported (range 19 to 39).	Intervention: Enoxaparin, 40 mg self-administered injections subcutaneously in the abdominal region once daily for 90 days n=20. Control: Placebo injection (saline) n=20. Follow-up time: Immediately post-treatment and 3 months post-treatment. Drop-out: I:1/20 (5%) C: 1/20 (5%).	Pain during sexual intercourse, % reduction*: *3 months post-treatment:* I: 28.9 C: 4.4 (p=0.057). Vulvar pain assessed with q-tip test, % reduction in NRS (0-10): *Post-treatment:* I: 24.0 C: 13.1 (p=0.018). *3 months post-treatment:* I: 29.6% C: 11.2% (p=0.004).		Serious adverse events: "there were no significant side effects".	Risk of bias: Moderate Blinding: Patients, treatment providers and assessors blinded. Comment: *Data was derived from one of the following questionnaires used in the study: Brief Pain Inventory, short form McGill Pain Questionnaire or the International Society for the Study of Vulvovaginal Disease vulvodynia questionnaire
Foster et al. 2010 [7] USA	Study design: RCT, multicentre with four treatment arms.	Intervention: 3 treatment arms for 12 weeks: I-A: Topical lidocaine cream	Pain during intercourse: VAS (range 0-10) change from baseline, mean (SD): I-A: -1.92 (1.82) n=21	Index of sexual satisfaction (range 0-100), change from baseline, mean (SD):	Serious adverse events: I-A: 0/33 (0%) I-B: 0/33 (0%)	Risk of bias Low Blinding:

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
	Patient characteristics: Provoked localized vulvodynia. n=133. Mean age: 33 (inclusion criteria 18 to 50).	5%, administered 4 times/day + placebo tablets, n=33. I-B: Oral desipramine 150 mg/day + placebo cream, n= 33. I-C: Oral desipramine 150 mg/day + topical lidocaine cream 5% 4 times/day, n=34 Control: Placebo tablets + placebo cream, n=33. Follow-up time: Immediately post-treatment. Drop-out: I: 5/33 (15%) I-B: 6/33 (18%) I-C:8/34 (24%) C: 2/33 (6%).	I-B: -2.07 (2.31) n=21 I-C: -1.72 (1.99) n=21 C: -1.97 (2.47) n=26 (all comparisons ns). Pain during cotton swab test, VAS (range 0-3), change from baseline, mean (SD). I-A: -6.42 (7.90) n=32 I-B: -8.07 (10.23) n=32 I-C: -11.37 (8.00) n=34 C: -8.65 (6.59) n=33 (all comparisons ns).	I-A: 0.43 (11.71) n=24 I-B: -6.86 (10.30) n=28 I-C: -6.32 (10.43) n=30 C: 0.69 (9.28) n=28 (all comparisons ns). Becks Depression Inventory (range 0-63), change from baseline, mean (SD): I-A: -0.86 (5.90) n=30 I-B: -3.33 (5.26) n=27 I-C: -1.77 (7.58) n=32 C: -1.92 (5.44) n=29 (all comparisons ns).	I-C: 0/34 (0%) C: 0/33 (0%). Mild adverse events, %: I-A: 0/33 (0%) I-B: 1/33 (3%) I-C: 1/34 (3%) C: 0/0 (0%).	Patients and treatment providers blinded.
Haraldsson et al. 2020 [8] Sweden	Study design: RCT, single centre. Patient characteristics: Provoked	Intervention: Botulinum toxin A, 50 units injected bilaterally in the bulbocavernosus muscles, 2 treatments with 3 months interval.	Pain during sexual intercourse or tampon use, VAS (0-100), mean (SD): *Average during posttreatment period (from assessment at 3 and 6*	FSFI, mean (SD): *Average from assessment at 3 and 6 months:* I: 20.9 (6.8) C: 19.5 (5.9) MD: 1.37 (95% CI -0.90	Serious adverse events: I: 0/41 C: 0/42. Mild adverse events: ns (data not	Risk of bias: Low Blinding: Patients, treatment providers and

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
	vestibulodynia. n=88. Mean age: Not reported, (inclusion criteria 18 to 40).	n=44. Control: Placebo injection (saline) n=44. Follow-up time: 1.5-, 3-, 4.5- and 6-months post-allocation. Drop-out: I:3/44 (7%) C: 2/44 (5%).	*months):* I: 51.7 (25.7) C: 59.0 (25.0) MD: -7.27 (95% CI -14.97 to 0.44). *3 months post-allocation:* I: 50.3 (25.1) C: 61.8 (23.6) MD -11.49 (95% CI 21.82 to -1.16), (p<0.05). *6 months post-allocation:* I: 53.3 (26.5) C: 55.9 (26.4) MD -2.66 (-14.37 to 9.05), (ns).	to 3.67), (ns).	reported).	assessors blinded.
Langlais et al. 2017 [9] Canada	Study design: RCT Patient characteristics: Secondary provoked vestibulodynia. n=20. Mean age: 22 (range 18 to 27).	Intervention: Estrogen cream, topical self-administration of cream containing 0.3 mg of conjugated equine estrogen every night and after intercourse, for 8 weeks n=10. Control: Placebo cream n=10.	Pain during sexual intercourse, VAS (range 0-10), % reduction (95% CI) I: 27 (-1 to 55) C: 3 (-8 to 14) (p=0.29). Unadjusted RR for 10% improvement (95% CI): 1.40 (0.67 to 2.94).	FSFI, unadjusted RR for 10% improvement (95% CI): 1.33 (0.74 to 2.41).	Mild adverse events (pruritus): I: 0/10 (0%) C: 3/10 (30%).	Risk of bias Low Blinding: Patients and treatment providers blinded.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
		Follow-up time: Immediately post-treatment. Drop-out: I: 0/10 (0%) C: 0/10 (0%).				
Murina et al. 2013 [10] Italy	Study design: RCT, single centre. Patient characteristics: Provoked localized vulvodynia. n=20. Mean age: 28 (range 18 to 48).	Intervention: Oral palmitoylethanolamide (PEA) 400 mg+ transpolydatine 40 mg, twice daily for 60 days. n=10. Control: Placebo tablets n=10. Follow-up time: Immediately post-treatment. Drop-out: I: 0/10 (0%) C: 0/10 (0%).	Pain during intercourse, Marinoff dyspareunia scale (0-3) post treatment, mean (SD): I: 1.0 (0.9) C: 1.1 (0.9) (ns)		Serious adverse events: I: 0/10 (0%) C: 0/10 (0%). Mild adverse events (transient gastrointestinal symptoms): I: 2/10 (20%) C: 1/10 (10%).	Risk of bias: Moderate Blinding: Patients and treatment providers blinded. Comments: All patients received vaginal TENS therapy in a self-administered protocol 3 times each week.
Murina et al. 2018 [11] Italy	Study design: RCT, single centre. Patient characteristics: Provoked localized	Intervention: Diazepam, 5 mg, self-administration of one vaginal tablet every day for 60 days n=21.	Pain during intercourse, Marinoff dyspareunia scale (0-3) change from baseline. I: 0.9 C: 0.7 (p<0.01).		Serious adverse events: I: 0/21 (0%) C: 0/21 (0%). Mild adverse events,	Risk of bias: Low Blinding: Patients and treatment providers

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
	vulvodynia. n=42. Mean age: 29.0 (SD 7.8)	Control: Placebo tablet. n=21. Follow-up: Immediately post-treatment. Drop-out: I: 0/21 (0%) C: 0/21 (0%).			(drowsiness): I: 2/21 (10%) C: 0/21 (0%).	blinded. Comments: All patients had vaginal TENS therapy in a self-administered protocol 3 times each week.
Nyiresy et al. 2001 [12] USA	Study design: RCT, two centres. Patient characteristics: Provoked localized vulvodynia. n=34. Mean age: 27 (range 24 to 49).	Intervention: Cromolyn cream 4%, topical self-administration 3 times daily for 3 months n=16. Control: Placebo cream n=18. Follow-up time: Immediately post-treatment. Drop-out: I: 3/16 (%) C: 5/18 (%).	50% self-rated overall improvement: I: 5/13 (38%) C: 6/13 (46%) (ns). Decrease in symptoms of irritation, burning, and dyspareunia (range 0-3), mean (IQR): I: 0 (0-1) C: 1 (1-2) (ns).		Serious adverse events: I: 0/13 (0%) C: 0/13 (0%). Mild adverse events (stinging at application): I: 2/13 (17%) C: 0/13 (0%).	Risk of bias: Moderate Blinding: Patients, treatment providers and assessors blinded.
Petersen et al.	Study design:	Intervention:	Pain during sexual activity,	FSFI, mean (SD):	Serious adverse	Risk of bias:

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
2009 [13] Denmark	RCT, single-centre. Patient characteristics: Provoked vestibulodynia. n=65. Mean age: 30 (SD 6).	Botulinum toxin A, 20 units injected in the Bulbospongiosus muscle at one occasion. n=33. Control: Placebo injection (saline). n=32. Follow-up time: 6 months post-treatment. Drop-out: I:4/33 (12%) C: 1/32 (3%).	patients with ≥2 VAS point reduction: I: 14/29 (44%) C: 16/31 (50%) (p=0.893). VAS (0–10), mean (SD): I: 5.14 (1.53)* C: 5.13 (1.53)*. VAS change from baseline, difference between groups: Cohen's d=0 (p=0.98).	I: 18.46 (9.27), n=24 C: 20.34 (6.69), n=21 (ns). SF-36: (ns, data not reported in numbers).	events: I: 0/29 (0%) C: 0/31 (0%). Mild adverse events: I: 4/29 (14%) C: 2/31 (6%).	Low Blinding: Patients and treatment providers blinded. Comments: *SD pooled from I+C group.

BDI = Beck depression inventory (range 0-63, higher=worse); C = Control; CI = Confidence interval; FSFI = Female sexual function index (range 2-36, higher=better); I = Intervention; Index of sexual satisfaction (range 0-100, higher=better); IQR = Interquartile range; MD = Mean difference; MDS = Marinoff dyspareunia scale (range 0-3, higher=worse); MPQ = McGill Pain Questionnaire (range 0-78, higher=worse); OR = Odds ratio; PROMIS = Patient-Reported Outcomes Measurement Information System; RCT = Randomized controlled study: RR = Risk ratio; NRS = Numeric rating scale (range 0-10 or 0-100, higher=worse); NRSI = Non-randomized controlled study; State-Trait Anxiety Inventory of Spielberger (range 20-80, higher=worse); Standard deviation; TENS = Transcutaneous electrical nerve stimulation; VAS = Visual analogue scale (range 0-10 or 0-100, higher=worse).

All data have been extracted from the original studies unless otherwise stated. P-values represent comparisons between groups, as reported in the original study.

Table 2 Physiotherapy treatment.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
Danielsson et al. 2006 [14] Sweden	Study design: RCT, two centres. Patient characteristics: Provoked vestibulodynia. n=46. Mean age: 25 (range 18 to 36).	Intervention: Electromyographic biofeedback, 3 professional-administered sessions + 3 daily 10-min self-administered sessions for 4 months n=23. Control: Lidocaine treatment, topical application of 2% or 5% ointment gel 5-7 times daily for 4 months n=23. Follow-up time: Immediately post-treatment, 6- and 12-months post-treatment. Drop-out: I: 5/23 (22%) C: 4/23 (17%).	Pain during sexual intercourse, VAS (range 0-100), median (IQR): *12 months post-treatment:* I: 65 (28-74) C: 42 (21-72) (ns). Pain at pressure assessed with vulvar-algesiometer, increase in pressure threshold (range 3-1000g). I: site A 45 g, site B 20 g C: site A 20 g, site B 10g (ns).	Sexual satisfaction, VAS 0-100 (higher=better), median (IQR): *12 months post-treatment:* I: 47 (25-55) C: 63 (25-77) (ns). Quality of life, joy of living VAS 0-100 (higher=better), median (IQR). *12 months post-treatment:* I: 69 (57-80) C: 64 (42-80) (ns).	Mild adverse events: I: Pain on insertion of the vaginal probe (numbers not reported), and one case of candida infection C: Stinging pain at application (numbers not reported).	Risk of bias: Moderate Blinding: No blinding.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
Hullender Rubin et al. 2019 [15] USA	Study design RCT, single centre. Patient characteristics: Provoked vestibulodynia. n=19 Mean age: 29 (range 19 to 45).	Intervention: Traditional acupuncture, manually needling on 5 points followed by manual and electrical stimulation, 18 sessions over 12 weeks. n=10. Control: Non-traditional acupuncture, 4 needles on nonspecific points and sham stimulation, 18 sessions over 12 weeks. n=9. Follow-up time: Post-treatment and 12 weeks post-treatment. Drop-out: I: 3/10 (30%) C: 2/9 (22%).	Pain during sexual intercourse, VAS (range 0-100), mean during study period (SD): I: 30.5 (2.3) C: 39.3 (3.0) (p=0.53). Vulvar pain assessed with cotton swab test, VAS (range 0-100), mean change from baseline (SD): *Post-treatment:* I: −23.9 (28.7) C: −25.9 (14.3) (ns). *12 weeks post-treatment* I: −18.5 (31.7) C: −31.4 (18.3) (ns).		Mild adverse events, number of events: I: 32 C: 36. Serious adverse events, number of events: I: 0 C: 0.	Risk of bias Moderate Blinding: Patients and data analysts blinded. Comments: Both groups were instructed to apply lidocaine cream 4 times daily.
Morin et al. 2020 [16] Canada	Study design: RCT, multicentre. Patient characteristics: Provoked	Intervention: Physical therapy treatment, 10 weeks of individual 1-hour sessions including education, pelvic floor muscle exercises with	Pain during sexual intercourse, NRS (range 0-10), MD between groups (95% CI): *Post-treatment* 1.8 (1.2 to 2.3).	FSFI (range 2-36), MD between groups (95% CI): *Post-treatment* -4.4 (-6.1 to -2.7) n=201, p<0.001.	Serious adverse events: I: 0/99 (0%) C: 0/103 (0%). Mild adverse events:	Risk of bias: Moderate Blinding: Assessors blinded.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
	vestibulodynia. n=212. Median age: 22 (IQR 21 to 26).	biofeedback, manual therapy, and dilation. n=105. Control: Lidocaine treatment, topical overnight application of 5% ointment cream every night for 10 weeks. n=107. Follow-up time: Immediately post-treatment and 6 months post-treatment. Drop-out: I: 11/105 (10%) C: 6/107 (6%).	n=201, p<0.001. *At 6 months:* 1.8 (1.2 to 2.5), n=195, p<0.001.	*At 6 months:* -3.3 (-5.0 to -1.6), n=195, p<0.001.	I: 0/99 (0%) C: 16/103 (16%).	
Murina et al. 2008 [17] Italy	Study design: RCT, single centre. Patient characteristics: Provoked vestibulodynia. n=20. Mean age:	Intervention: Transcutaneous electrical nerve stimulation, 20 sessions of 30 min over 10 weeks. n=20. Control: Sham treatment (nonactive electrical stimulation), 20	Pain during sexual intercourse, MDS (range 0-3), mean (SD): *Post-treatment:* I: 1.1 (0.9) C: 2.4 (0.8). *3 months post-treatment:* I: 1.1 (0.9) C: 2.4 (0.8).	FSFI (range 2-36), mean (SD): *Post-treatment:* I: 25.3 (7.5) C: 17.8 (5.9). *3 months post-treatment:* I: 20.3 (7.5) C: 16.8 (5.9).	Adverse events: Not reported.	Risk of bias: Low Blinding: Patients blinded.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
	28 (range 21 to 44).	sessions of 30 min over 10 weeks. n=20. Follow-up time: Immediately post-treatment and 3 months post-treatment. Drop-out: I: 0/20 (0%) C: 0/20 (0%).				

BDI= Beck depression inventory (range 0-63, higher=worse); C=Control; CI=Confidence interval; FSFI=Female sexual function index (range 2-36, higher=better); I=Intervention; Index of sexual satisfaction (range 0-100, higher=better); IQR = Interquartile range; MD=Mean difference; MDS= Marinoff dyspareunia scale (range 0-3, higher=worse); MPQ=McGill Pain Questionnaire (range 0-78, higher=worse); OR=Odds ratio; PROMIS= Patient-Reported Outcomes Measurement Information System; RCT= Randomized controlled study: RR=Risk ratio; NRS=Numeric rating scale (range 0-10 or 0-100, higher=worse); NRSI= Non-randomized controlled study; Standard deviation; TENS=transcutaneous electrical nerve stimulation; VAS=Visual analogue scale (range 0-10 or 0-100, higher=worse);

All data have been extracted from the original studies unless otherwise stated. P-values represent comparisons between groups, as reported from analyses in the original study.

Table 3 Psychological treatment.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
Bergeron et al. 2001 [18] Canada Bergeron et al. 2008 [19] Canada	Study design: RCT comparing three interventions. Patient characteristics: Provoked vestibulodynia. n=87. Mean age: 26.8 years (SD 5.4).	Intervention 1: Group cognitive-behavioural therapy, (GCBT). Eight 2-hour groups sessions over a 12-week period. Intervention 2: Biofeedback, eight 45-minute sessions over a 12-week period. Biofeedback training involved self-insertion of a small sEMG sensor in the vagina. Intervention 3: *Vestibulectomy* (excision of the vestibular area to a depth of 2 mm and a width of 1 cm, all the way up to the urethra). Follow-up time: Immediately post-treatment and 6 months post-treatment (Bergeron 2001, [18]). 2.5 years post-treatment (Bergeron 2008, [19]).	Vestibular pain index assessed with cotton swab test, NRS 0-10. *Posttreatment, mean (SD)* GCBT 5.26 (2.00) Biofeedback 4.55 (2.36) Vestibulectomy 1.89 (1.68). Vestibulectomy had significantly lower posttreatment pain compared to GCBT ($p<0.01$) and biofeedback ($p<0.01$). *6 months, mean (SD)* GCBT 3.89 (2.09) Biofeedback 4.42 (2.63) Vestibulectomy 1.90 (2.24). Vestibulectomy had significantly lower pain compared to biofeedback ($p<0.05$) at 6 months. *2.5 years, mean (SD)* GCBT 3.66 (2.33) Biofeedback 4.22 (2.54) Vestibulectomy 1.58 (1.91) Vestibulectomy had significantly lower pain compared to GCBT ($p<0.01$) and biofeedback ($p<0.01$) at	Global sexual functioning (sexual history form, range 0-1). *Posttreatment, mean (SD)* GCBT 0.49 (0.12) Biofeedback 0.51 (0.08) Vestibulectomy 0.49 (0.14). *6 months, mean (SD)* GCBT 0.48 (0.11) Biofeedback 0.48(0.08) Vestibulectomy 0.45 (0.15). *2.5 years, mean (SD)* GCBT 0.46 (0.12) Biofeedback 0.48 (0.10) Vestibulectomy 0.43 (0.11).	Adverse events Not reported.	Risk of bias: Moderate for both studies. Blinding: No blinding. Comments: Drop out at 2.5 year follow up calculated on ITT population.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
		Drop-out at 6 months: I 1: 1/29 (3%) I 2: 1+2+8/29 (38%) I 3: 7+3/29 (35%). Drop-out 2.5 years: I 1: 10/29 (35%) I 2: 12/29 (41%) I 3: 14/29 (48%).	2.5 years. *Self-reported pain* (intensity of painful intercourse, NRS 0-10). *Posttreatment, mean (SD)* GCBT 6.00 (2.13) Biofeedback 5.43 (2.36) Vestibulectomy 3.93 (3.25). *6 months, mean (SD)* GCBT 4.46 (2.47) Biofeedback 4.50 (2.63) Vestibulectomy 3.41 (3.17). *2.5 years, mean (SD)* GCBT 3.30 (2.73) Biofeedback 4.29 (2.66) Vestibulectomy 2.05 (1.87).			
Bergeron et al. 2016 [20] Canada	Study design: RCT comparing two interventions. Patient characteristics: Provoked vestibulodynia. n=97. Mean age: 26.7 years (SD 6.1).	Intervention 1: Group cognitive-behavioural therapy (GCBT), 10 two-hour sessions over a 13-week period. n=52. Intervention 2 (Control): Topical steroid (twice daily application of 1% hydrocortisone cream) + written education materials about provoked vestibulodynia.	Pain during intercourse, (NRS 0-10), mean (SD). *Post treatment:* GCBT 5.46 (2.75) Topical steroid 5.67 (3.32) (p=0.55). *6 months:* GCBT 5.21 (2.87) Topical steroid 5.87 (3.07) (p=0.70).	FSFI (2-36, higher better functioning), mean (SD): *Post treatment:* GCBT 23.03 (7.59) Topical steroid 22.53 (7.63). (p=0.26). *6 months:* GCBT 22.33 (7.75) Topical steroid 23.30 (7.20) (p=0.63).	Adverse events: Not reported.	Risk of bias: Moderate Comments: Pain during intercourse was assessed only in those (n=92 at baseline) who were sexually active.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
		n=45. Follow-up time: Immediately post treatment, 6 months post-treatment. Drop-out: I: 17/52 (33%) C:16/45 (33%).				
Brotto et al 2019 [21] Canada Brotto et al. 2020 [22] Canada	Study design: Quasi-randomized clinical trial (47 participants were randomized and 83 were assigned non-randomly according to scheduling logistics). Patient characteristics: Provoked vestibulodynia. n=130. Mean age: 32 (SD 8).	Intervention: Mindfulness-based cognitive therapy (MBCT), 8 weekly group sessions of 2.25 h+ mindfulness home exercises n=67. Control: Cognitive behavioural therapy (CBT), 8 weekly group sessions of 2.25 h+ home exercises. n=63. Follow-up time: Post-treatment, 6- and 12-months post-treatment. Drop-out: *At 6 months (Brotto 2019,*	Pain during intercourse, NRS (range 0-10), mean (SD): *Post-treatment:* I: 4.34 (2.22) C: 4.65 (2.21) (p=0.03). *6 months post-treatment:* I: 3.39 (1.89) C: 4.03 (2.11) (p=0.02). *12 months post-treatment:* I: 3.62 (3.09) C: 3.97 (2.51) (p=0.53). Vulvar pain assessed with vulvalgesiometer (range 0-10), mean (SD): *Post-treatment:* I: 3.21 (1.96) C: 3.60 (2.14)	FSFI (range 2-36), mean (SD): *Post-treatment:* I: 21.79 (6.83) C: 23.41 (5.72) (p=0.72). *6 months post-treatment:* I: 24.75 (5.62) C: 23.20 (5.45) (p=0.09).	Adverse events: Not reported.	Risk of bias: Moderate for both studies. Blinding: No blinding. Comments: Pain during intercourse was assessed only in those (n=98) who were sexually active.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
		[21]): I: 8/67(12%) C: 14/63 (22%). *At 12 months (Brotto 2020 [22]):* I: 23/67 (34%) C: 18/63 (29%).	(p=0.34). *6 months post-treatment:* I: 2.92 (2.31) C: 2.86 (1.89) (p=1.00). *12 months post-treatment:* I: 2.52 (1.78) C: 2.00 (1.66) (p=0.27).			
Goldfinger et al. 2016 [23] Canada	Study design: RCT Patient characteristics: Provoked vestibulodynia n=20 Mean age: 26 (range 10 to 56).	Intervention: CBT program including education and home exercises, 8 individual sessions of 1.5 h for 8-24 weeks. n=10. Control: Physical therapy program including education and home exercises, 8 individual sessions of 1.5 h for 8-24 weeks. n=10. Follow-up time: Immediately post-treatment	Pain during sexual intercourse, VAS (range 0-10), mean reduction (SD): *Post-treatment:* I: 2.60 (1.43) C: 2.70 (2.36) (ns). *6 months post-treatment:* I: 2.10 (1.37) C: 2.40 (2.63) (ns). Vulvar pain assessed with cotton swab test VAS (range 0-10) *Post-treatment:* I: 3.26 (2.69) C: 1.28 (1.05) (p=0.03).	FSFI (range 2-36), mean (SD): *Post-treatment:* I: 27.37 (4.61) C: 27.06 (4.25) (ns). *6 months post-treatment:* I: 29.69 (5.12) C: 24.29 (7.18) (ns).	Adverse events: Not reported.	Risk of bias Moderate Blinding: No blinding. Comments: Outcomes on questionnaire data was based on 19 participants. P-values represent between-group effects from mixed-model analyses of variance (ANOVAs).

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
		and 6 months post-treatment. Drop-out: I: 0/10 (0%) C: 0/10 (0%).	*6 months post-treatment:* I: 2.62 (2.88) C: 1.86 (2.22) (ns).			
Guillet et al. 2019 [24] USA	Study design: RCT comparing two interventions. Patient characteristics: Provoked vestibulodynia. n=31. Mean age: 32 (SD 7).	Intervention 1: Mindfulness-based group cognitive behavioural therapy (M-gCBT), weekly sessions à 2.5 h for 8 weeks. n=14. Intervention 2 (Control): Education support, 8 weeks of online education with 3 in-person group visits. n=17. Follow-up time: Immediately post treatment, at 3 and at 6 months post-treatment. Drop-out: I: 0/14 C: 0/17.	Tampon test (NRS range 0-10) Between group change, MD (95% CI). *Post intervention:* 0.022 (−1.27 to 1.32), p=0.97 *3 months:* −0.67 (−2.04 to 0.70), p=0.34. *6 months:* −0.56 (−1.95 to 0.83), p=0.43.	FSFI, between group change, MD (95% CI) *Post intervention:* 12.5 (0.66 to 24.34), p=0.039 *3 months*: 15.12 (3.38 to 26.87), p=0.012 6 months: 12.10 (−0.041 to 24.24), p=0.051. Generalized Anxiety Disorder 7 (GAD-7; range 0–21), MD (95% CI) *Post intervention:* −3.39 (−5.78 to −1.00), p=0.006 *3 months:* −2.31 (−4.75 to 0.12) p=0.063. *6 months:* −2.83 (−5.27 to −0.40) p=0.023. Depression Beck Depression Inventory: (BDI-PC; range 0–63). *Post intervention:* −2.04	Adverse events: Not reported.	Risk of bias: Moderate

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	**Results:** • Pain during intercourse • Pain at pressure	**Results:** • Sexual function/satisfaction • Quality of life • Anxiety • Depression	**Results:** • Adverse events	Risk of bias Blinding Comments
				(−6.64 to 2.55) p=0.38 *3 months:* −3.52 (−8.25 to 1.20), p=0.14 *6 months:* −5.01 (−9.84 to −0.18), p=0.042.		

BDI = Beck depression inventory (range 0-63, higher=worse); C = Control; CI = Confidence interval; FSFI = Female sexual function index (range 2-36, higher=better); GCBT = Group cognitive-behavioural therapy; I = Intervention; Index of sexual satisfaction (range 0-100, higher=better); MD = Mean difference; MDS = Marinoff dyspareunia scale (range 0-3, higher=worse); M-gCBT = Mindfulness-based group cognitive behavioural therapy; MPQ = McGill Pain Questionnaire (range 0-78, higher=worse); OR = Odds ratio; PROMIS = Patient-Reported Outcomes Measurement Information System; RR =Risk ratio; NRS = Numeric rating scale (range 0-10 or 0-100, higher=worse); SD = Standard deviation; sEMG = Surface Electromyography; TENS = Transcutaneous electrical nerve stimulation; VAS = Visual analogue scale (range 0-10 or 0-100, higher=worse);

All data including p-values have been extracted from the original studies. P-values represent comparisons between groups, as reported from analyses in the original study.

Table 4 Other treatments.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
Gruenwald et al. 2021 [25] Israel	Study design: RCT, single centre. Patient characteristics: Provoked vestibulodynia. n=34. Mean age: I: 27 years (SD 8) C: 25 years (SD 9).	Intervention: Low intensity shock wave therapy twice a week for 6 weeks. Each treatment consisted of 500 pulses of shockwaves (0.09 mJmm2) n=23. Control: Sham treatment given at same treatment protocol n=9. Follow-up time: 1- and 3-month post treatment. Drop-out: I: 1/24 (4%) C: 1/10 (10%).	Pain during sexual intercourse, VAS range 0-10, mean (SD). *1-month post-treatment:* I: 5.70 (2.3) C: 8.30 (1.6). *3 months post-treatment:* I: 4.4 (2.5) C: 7.90 (2.2). Pain threshold, assessed with algometer test as applied radial pressure (mmHg) for first pain sensation, mean (SD). *1-month post-treatment:* I: 34.7 (18.8) C: 26.9 (10.3). *3 months post-treatment:* I: 69.8 (11.8) C: 34.9 (35.1).	FSFI (range 2-36), mean (SD). *1-month post-treatment:* I: 20.9 (6.2) C: 21.9 (4.7). *3 months post-treatment:* I: 22.5 (8.0) C: 21.1 (5.1).	Mild adverse events: I: 1/23 (4%) (low abdominal pain) C: 0/9 (0%).	Risk of bias: Moderate
Lev-Sagie et al. 2017 [26]	Study design: RCT, single centre, with a blinded phase of 6 weeks and an unblinded	Intervention: Low-level laser therapy, non-thermal pulsed light irradiation at the vestibule,	Pain during sexual intercourse according to diary, NRS (range 0-10), change from baseline, mean (SD):	Satisfaction with overall sexual life, any inference, n/N, post-treatment: I: 59%	Adverse events: I: 0/18 C: 0/17.	Risk of bias: Moderate Blinding: Patients and

Author **Year** **Reference** **Country**	**Study design** **Patient characteristics**	**Intervention** **Control** **Follow-up time** **Drop-outs**	**Results:** • **Pain during intercourse** • **Pain at pressure**	**Results:** • **Sexual function/satisfaction** • **Quality of life** • **Anxiety** • **Depression**	**Results:** • **Adverse events**	**Risk of bias** **Blinding** **Comments**
Israel	phase (data only extracted from blinded phase). Patient characteristics: Provoked vestibulodynia. n=34. Mean age: 26 (range 19-46).	2 weekly sessions for 6 weeks. n=18. Control: Sham treatment given at same treatment protocol. n=17. Follow-up time: Immediately post-treatment. Drop-out: I: 0/18 (0%) C: 1/17 (6%).	I: 0.9 (1.94) C: 0.10 (1.99) (p=0.245). Vulvar pain assessed with cotton swab test, NRS (range 0-100), change from baseline, mean (SD): I: 6.3 (2.8) C: 7.0 (9.1) (p=0.954).	C: 87% (p=0.507).		treatment providers blinded.
Morin et al. 2017 [27] Canada	Study design: RCT, single centre. Patient characteristics: Provoked vestibulodynia. n=40. Mean age: 22 (IQR 20 to 24).	Intervention: Transcranial direct-current stimulation, 10 sessions of 20 minutes over 2 weeks. n=20. Control: Sham treatment at same treatment protocol. n=20. Follow-up time: Immediately post-treatment, and 3 months post-	Pain during sexual intercourse, VAS (range 0-10), change from baseline, mean (95% CI): *Post-treatment:* I: 1.2 (0.4 to 2.1) C: 1.8 (0.8 to 2.8) (p=0.84). *3 months post-treatment, difference between groups:* P=0.09.	FSFI (range, 2-36), mean (95% CI): *Post-treatment:* I: 23.9 (21.3 to 26.5) C: 22.2 (19.7 to 24.7) (p=0.35). *3 months post-treatment:* I: 23.4 (20.8 to 26.0) C: 23.9 (21.3 to 26.4) (p=0.79). STAI, state domain, mean (95% CI):	Adverse events, total number of events: I: 94 C: 73.	Risk of bias: Low Blinding: Patients, treatment providers and assessors blinded.

Author Year Reference Country	Study design Patient characteristics	Intervention Control Follow-up time Drop-outs	Results: • Pain during intercourse • Pain at pressure	Results: • Sexual function/satisfaction • Quality of life • Anxiety • Depression	Results: • Adverse events	Risk of bias Blinding Comments
		treatment. Drop-out: I: 1/20 (5%) C: 0/20 (0%).		*Post-treatment:* I: 35.2 (31.3 to 39.7) C: 32.8 (29.2 to 36.8) (p=0.39). *3 months post-treatment:* I: 34.0 (30.2 to 38.3) C: 30.0 (26.7 to 33.7) (p=0.14). BDI (range, 0-63), mean (95% CI): *Post-treatment:* I: 5.3 (3.5-7.9) C: 5.5 (3.7-8.1) (p=0.92). *3 months post-treatment:* I: 5.0 (3.4 to 7.5) C: 4.1 (2.8 to 6.1) (p=0.48).		

BDI= Beck depression inventory (range 0-63, higher=worse); C=Control; CI=Confidence interval; FSFI=Female sexual function index (range 2-36, higher=better); I=Intervention; Index of sexual satisfaction (range 0-100, higher=better); IQR = Interquartile range; MD=Mean difference; MDS= Marinoff dyspareunia scale (range 0-3, higher=worse); MPQ=McGill Pain Questionnaire (range 0-78, higher=worse); OR=Odds ratio; PROMIS= Patient-Reported Outcomes Measurement Information System; RCT= Randomized controlled study: RR=Risk ratio; NRS=Numeric rating scale (range 0-10 or 0-100, higher=worse); NRSI= Non-randomized controlled study; SD=Standard deviation; STAI=State-Trait Anxiety Inventory of Spielberger (range 20-80, higher=worse), TENS=transcutaneous electrical nerve stimulation; VAS=Visual analogue scale (range 0-10 or 0-100, higher=worse);

All data have been extracted from the original studies unless otherwise stated. P-values represent comparisons between groups, as reported from analyses in the original study.

References

1. Brown CS, Bachmann GA, Wan J, Foster DC, Gabapentin Study G. Gabapentin for the Treatment of Vulvodynia: A Randomized Controlled Trial. Obstet Gynecol. 2018;131(6):1000-07. Available from: https://doi.org/10.1097/AOG.0000000000002617.
2. Bachmann GA, Brown CS, Phillips NA, Rawlinson LA, Yu X, Wood R, et al. Effect of gabapentin on sexual function in Vulvodynia: A randomized, placebo-controlled trial. Obstet Gynecol Surv. 2019;74(2):82-83. Available from: https://doi.org/10.1016/j.ajog.2018.10.021.
3. Bornstein J, Tuma R, Farajun Y, Azran A, Zarfati D. Topical nifedipine for the treatment of localized provoked vulvodynia: a placebo-controlled study. J Pain. 2010;11(12):1403-09. Available from: https://doi.org/10.1016/j.jpain.2010.03.016.
4. Diomande I, Gabriel N, Kashiwagi M, Ghisu GP, Welter J, Fink D, et al. Subcutaneous botulinum toxin type A injections for provoked vestibulodynia: a randomized placebo-controlled trial and exploratory subanalysis. Arch Gynecol Obstet. 2019;299(4):993-1000. Available from: https://doi.org/10.1007/s00404-019-05043-w.
5. Donders GG, Bellen G. Cream with cutaneous fibroblast lysate for the treatment of provoked vestibulodynia: a double-blind randomized placebo-controlled crossover study. J Low Genit Tract Dis. 2012;16(4):427-36. Available from: https://doi.org/10.1097/LGT.0b013e31825a2274.
6. Farajun Y, Zarfati D, Abramov L, Livoff A, Bornstein J. Enoxaparin treatment for vulvodynia: a randomized controlled trial. Obstet Gynecol. 2012;120(3):565-72. Available from: https://doi.org/10.1097/AOG.0b013e3182657de6.
7. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol. 2010;116(3):583-93. Available from: https://doi.org/10.1097/AOG.0b013e3181e9e0ab.
8. Haraldson P, Muhlrad H, Heddini U, Nilsson K, Bohm-Starke N. Botulinum Toxin A as a Treatment for Provoked Vestibulodynia: A Randomized Controlled Trial. Obstet Gynecol. 2020;136(3):524-32. Available from: https://doi.org/10.1097/AOG.0000000000004008.
9. Langlais EL, Lefebvre J, Maheux-Lacroix S, Bujold E, Fortier M, Bouchard C. Treatment of Secondary Vestibulodynia with Conjugated Estrogen Cream: A Pilot, Double-Blind, Randomized Placebo-Controlled Trial. Journal of Obstetrics & Gynaecology Canada: JOGC. 2017;39(6):453-58. Available from: https://doi.org/10.1016/j.jogc.2016.10.011.
10. Murina F, Graziottin A, Felice R, Radici G, Tognocchi C. Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. J Low Genit Tract Dis. 2013;17(2):111-16. Available from: https://doi.org/10.1097/LGT.0b013e3182652316.
11. Murina F, Felice R, Di Francesco S, Oneda S. Vaginal diazepam plus transcutaneous electrical nerve stimulation to treat vestibulodynia: A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2018;228:148-53. Available from: https://doi.org/10.1016/j.ejogrb.2018.06.026.
12. Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Small MJ, Gelone SP. Cromolyn cream for recalcitrant idiopathic vulvar vestibulitis: results of a placebo controlled study. Sex Transm Infect. 2001;77(1):53-57. Available from: https://doi.org/10.1136/sti.77.1.53.
13. Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo

controlled, double blinded study. J Sex Med. 2009;6(9):2523-37. Available from: https://doi.org/10.1111/j.1743-6109.2009.01378.x.
14. Danielsson I, Torstensson T, Brodda-Jansen G, Bohm-Starke N. EMG biofeedback versus topical lidocaine gel: a randomized study for the treatment of women with vulvar vestibulitis. Acta Obstet Gynecol Scand. 2006;85(11):1360-67. Available from: https://doi.org/10.1080/00016340600883401.
15. Hullender Rubin LE, Mist SD, Schnyer RN, Chao MT, Leclair CM. Acupuncture Augmentation of Lidocaine for Provoked, Localized Vulvodynia: A Feasibility and Acceptability Study. J Low Genit Tract Dis. 2019;23(4):279-86. Available from: https://doi.org/10.1097/LGT.0000000000000489.
16. Morin M, Dumoulin C, Bergeron S, Mayrand MH, Khalife S, Waddell G, et al. Multimodal physical therapy versus topical lidocaine for provoked vestibulodynia: a prospective, multicenter, randomized trial. Am J Obstet Gynecol. 2020;18:18. Available from: https://doi.org/https://dx.doi.org/10.1016/j.ajog.2020.08.038.
17. Murina F, Bianco V, Radici G, Felice R, Di Martino M, Nicolini U. Transcutaneous electrical nerve stimulation to treat vestibulodynia: a randomised controlled trial. BJOG. 2008;115(9):1165-70. Available from: https://doi.org/10.1111/j.1471-0528.2008.01803.x.
18. Bergeron S, Binik YM, Khalife S, Pagidas K, Glazer HI, Meana M, et al. A randomized comparison of group cognitive--behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. Pain. 2001;91(3):297-306.
19. Bergeron S, Khalife S, Glazer HI, Binik YM. Surgical and behavioral treatments for vestibulodynia: two-and-one-half year follow-up and predictors of outcome. Obstet Gynecol. 2008;111(1):159-66. Available from: https://doi.org/10.1097/01.AOG.0000295864.76032.a7.
20. Bergeron S, Khalife S, Dupuis MJ, McDuff P. A randomized clinical trial comparing group cognitive-behavioral therapy and a topical steroid for women with dyspareunia. J Consult Clin Psychol. 2016;84(3):259-68. Available from: https://doi.org/10.1037/ccp0000072.
21. Brotto LA, Bergeron S, Zdaniuk B, Driscoll M, Grabovac A, Sadownik LA, et al. A Comparison of Mindfulness-Based Cognitive Therapy Vs Cognitive Behavioral Therapy for the Treatment of Provoked Vestibulodynia in a Hospital Clinic Setting. J Sex Med. 2019;16(6):909-23. Available from: https://doi.org/10.1016/j.jsxm.2019.04.002.
22. Brotto LA, Bergeron S, Zdaniuk B, Basson R. Mindfulness and cognitive behavior therapy for provoked vestibulodynia: Mediators of treatment outcome and long-term effects. J Consult Clin Psychol. 2020;88(1):48-64.
23. Goldfinger C, Pukall CF, Thibault-Gagnon S, McLean L, Chamberlain S. Effectiveness of Cognitive-Behavioral Therapy and Physical Therapy for Provoked Vestibulodynia: A Randomized Pilot Study. J Sex Med. 2016;13(1):88-94. Available from: https://doi.org/10.1016/j.jsxm.2015.12.003.
24. Guillet AD, Cirino NH, Hart KD, Leclair CM. Mindfulness-Based Group Cognitive Behavior Therapy for Provoked Localized Vulvodynia: A Randomized Controlled Trial. J Low Genit Tract Dis. 2019;23(2):170-75. Available from: https://doi.org/10.1097/LGT.0000000000000456.
25. Gruenwald I, Gutzeit O, Petruseva A, Gartman I, Lowenstein L. Low-Intensity Shockwave for Treatment of Vestibulodynia: A Randomized Controlled Therapy Trial. J Sex Med. 2021;05:05. Available from: https://doi.org/https://dx.doi.org/10.1016/j.jsxm.2020.11.006.
26. Lev-Sagie A, Kopitman A, Brzezinski A. Low-Level Laser Therapy for the Treatment of Provoked Vestibulodynia-A Randomized, Placebo-Controlled Pilot Trial. J Sex

Med. 2017;14(11):1403-11. Available from: https://doi.org/10.1016/j.jsxm.2017.09.004.

27. Morin M, Binik YM, Bourbonnais D, Khalife S, Ouellet S, Bergeron S. Heightened Pelvic Floor Muscle Tone and Altered Contractility in Women With Provoked Vestibulodynia. J Sex Med. 2017;14(4):592-600. Available from: https://doi.org/10.1016/j.jsxm.2017.02.012.